ABSTRACT
INTRODUCTION
Diagnosing fetal heart failure remains challenging because it is difficult to know how well the fetal myocardium will perform when loading conditions change 1 . Recently, the cardiovascular profile (CVP) score has been shown to be a superior marker for comprehensive and semiquantitative assessment of fetal heart failure manifesting as fetal hydrops 2, 3 . The role of the CVP score in the prognosis of fetuses with congenital heart defects (CHDs) has been studied [4] [5] [6] . The American Heart Association statements mention that it may be useful in baseline and serial evaluation of fetuses at risk for, or with, myocardial dysfunction 7 .
In adult cardiology, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are established markers of heart failure [8] [9] [10] . However, few studies have investigated natriuretic peptide (NP) levels in fetuses with CHD [11] [12] [13] [14] . It has not been clearly established whether plasma NP levels in umbilical cord blood are indicators of fetal heart failure. In addition, to the best of our knowledge, there have been no studies investigating NP levels in fetuses with arrhythmia, although fetal tachy-or bradyarrhythmias are common causes of fetal hydrops [15] [16] [17] . The aim of this study was to evaluate the significance of plasma NP levels in the assessment of fetal heart failure by comparing the pathophysiological status of fetuses with CHD and arrhythmia. We prospectively observed changes in CVP scores in utero and measured umbilical-cord blood NP levels at birth.
METHODS
A single-center prospective observational study was undertaken with approval from our institutional review board (M24-041) and with written informed consent from the fetuses' parents. All singletons diagnosed prenatally with CHD and/or arrhythmia at the National Cerebral and Cardiovascular Center, Suita, Japan, between October 2012 and December 2015 were included in the study. Exclusion criteria included a critical chromosomal anomaly such as trisomy 13 or 18, or a critical extracardiac anomaly that required surgical intervention during the neonatal period. Control subjects were normal fetuses with no complications such as CHD, extracardiac anomaly or growth restriction, and were recruited randomly. Subjects were excluded if they had a maternal or obstetric complication such as chronic hypertension, diabetes mellitus, pre-eclampsia or gestational diabetes mellitus. Cases and controls with no blood sample available at birth were also excluded from the analysis.
CVP score was used to characterize fetal heart failure 7 . CVP scores of all cases were evaluated by the same person. CVP score is based on a proposed composite scoring system to grade and serially follow the severity of fetal heart failure using five fetal echocardiographic parameters: fetal effusion, venous Doppler findings, heart size, cardiac function and arterial Doppler findings. Heart failure severity is rated on a 10-point scale; points are deducted for abnormalities in each component marker [2] [3] [4] . A CVP score of ≥ 8 is considered to indicate no or mild heart failure, 6 or 7 indicates moderate heart failure and ≤ 5 indicates severe heart failure 6 . The CVP score data of 62 fetuses in the CHD group were presented in our previous study focused on CVP score as a predictor of acute intrapartum non-reassuring fetal status in infants with CHD 18 ; the umbilical-cord blood NP data have not been published previously in any form.
All fetuses with CHD were diagnosed prenatally by fetal echocardiography using Voluson E8 ultrasound equipment (GE Medical Systems, Zipf, Austria). CHDs were categorized morphologically as in our previous study 18 . Our tertiary pediatric cardiac center has an established protocol for patients with a prenatal diagnosis of CHD or arrhythmia 18 . Patients are admitted to the hospital and assessed at least weekly for CVP and biophysical profile scores after 37 weeks' gestation or if they have a complication such as threatened labor or fetal growth restriction. Therefore, all fetuses had CVP score assessed within 1 week before birth.
All cases of fetal arrhythmia were diagnosed using fetal echocardiography and magnetocardiography (MC-6400, Hitachi High-Technologies Corporation, Tokyo, Japan). Fetal arrhythmias were categorized as tachy-or bradyarrhythmia, or extrasystole. Fetal tachy-and bradyarrhythmias were defined by ventricular rates of ≥ 180 bpm and < 100 bpm, respectively. When fetal tachyarrhythmia was sustained for ≥ 50% of the time on monitoring before 37 weeks' gestation, fetal therapy was performed. Digoxin, sotalol, flecainide or a combination of these was used for supraventricular tachycardia or atrial flutter. Magnesium sulfate, propranolol, mexiletine or a combination of these was used for ventricular tachycardia. When complete atrioventricular block was complicated by fetal ventricular rate of < 55 bpm with or without myocarditis before 34 weeks, fetal therapy using beta-sympathomimetics and/or steroids was performed.
Umbilical vein (UV) blood samples were collected at the time of delivery into test tubes containing disodium ethylenediaminetetraacetic acid (EDTA-2Na) and aprotinin (final concentrations: 1.5 mg/mL and 500 kallikrein inhibitor units/mL, respectively). Blood samples were chilled on ice. Plasma samples were prepared by centrifugation at 1500 g for 15 min at 4
• C and immediately frozen at -80 • C until assays were performed. UV plasma ANP and BNP concentrations were measured using the AIA-PACK chemiluminescence immunoassay (TOSOH Corporation, Tokyo, Japan). An electrochemiluminescence immunoassay (Elecsys NT-proBNP II, Roche Diagnostics, Basel, Switzerland) was used to assess NT-proBNP concentrations in UV blood samples. Statistical analysis was performed using Stata version 14.1 (StataCorp LP, College Station, TX, USA) and JMP 10 (SAS Institute, Cary, NC, USA). Student's t-test was used to compare continuous variables between groups. Categorical variables were evaluated using the chi-square or Fisher's exact test, as appropriate, and correlations between NP levels and CVP score were evaluated using the trend test. Univariate and multivariate logistic regression analysis of NP levels was performed in fetuses with CHD and/or arrhythmia. The best prediction model was selected using backward stepwise elimination, with P ≥ 0.10 as the criterion for exclusion, which was adjusted for baseline variables, and P < 0.05 was considered to indicate statistical significance in all analyses.
RESULTS

Study cohort and baseline characteristics
A total of 143 fetuses with CHD and/or arrhythmia and 137 control fetuses were enrolled prospectively in the study (Figure 1 ). In the CHD and/or arrhythmia group, four cases of fetal demise, three cases of trisomy 18 and seven cases with sampling failure were excluded, leaving 129 fetuses available for analysis. The four fetal deaths were due to Ebstein's anomaly, with circular shunt in two cases, dilated cardiomyopathy in one case and double outlet right ventricle with severe fetal growth restriction in one case. Among the controls, one case of fetal hydronephrosis and nine cases of sampling failure were excluded, leaving 127 fetuses available for analysis. Baseline perinatal characteristics are shown in Table 1 . All controls had normal fetal growth and a CVP score of 10. In the control group, Cesarean delivery was performed mainly because of previous Cesarean delivery.
The types of CHD and arrhythmia among study participants are shown in Table 2 . All diagnoses of CHD were confirmed soon after birth using echocardiography by pediatric cardiologists. Arrhythmias complicated by CHD were included only in the arrhythmia group. One fetus with supraventricular tachycardia had a cardiac tumor, two fetuses with complete atrioventricular block and two fetuses with sinus bradycardia had left atrial isomerism, and four fetuses with atrial extrasystole had an atrioventricular septal defect. Fetal therapy was performed in 22 fetuses with arrhythmia: supraventricular tachycardia or atrial flutter (n = 15), ventricular tachycardia (n = 2) or complete atrioventricular block (n = 5). At birth, five cases of tachyarrhythmia, 11 of bradyarrhythmia and eight of extrasystole were confirmed using electrocardiography.
NP levels and perinatal factors associated with CHD and/or arrhythmia
When examining the relationships between NP levels and CVP score in fetuses with CHD and/or arrhythmia and comparing NP levels of these fetuses with those in controls, UV-ANP and UV-BNP levels showed trends similar to that of UV-NT-proBNP level but to a lesser extent (Figures 2 and S1 ). Therefore, we present data on UV-NT-proBNP levels as representative of NP levels overall. Fetuses with CHD and/or arrhythmia had a 3.2-fold higher UV-NT-proBNP level than that of control fetuses (1935 ± 3965 pg/mL vs 613 ± 329 pg/mL; P < 0.01). After dividing these fetuses into three groups according to CVP score (≥ 8 (n = 107), 6 or 7 (n = 13) and ≤ 5 (n = 9)), we found that UV-NT-proBNP levels were correlated inversely with CVP score among cases (P for trend < 0.01), while no difference was observed in UV-NT-proBNP levels between fetuses with CHD and/or Nine fetuses had arrhythmia complicated by CHD but are included only in the arrhythmia group: one with supraventricular tachycardia had cardiac tumor; two with complete atrioventricular block and two with sinus bradycardia had left atrial isomerism; and four with atrial extrasystole had atrioventricular septal defect.
arrhythmia and a CVP score of ≥ 8 vs controls (P = 0.16) (Figure 2 ). To identify perinatal factors associated with high UV-NT-proBNP level, univariate and multivariate analysis was performed for fetuses with CHD and/or arrhythmia (Table 3 ). Multivariate analysis showed that a CVP score of ≤ 5, tachy-or bradyarrhythmia at birth, preterm birth and umbilical artery (UA) pH < 7.15 were associated independently with high levels of UV-NT-proBNP (P < 0.01). Similar results were obtained for UV plasma ANP and BNP levels. The main reasons for preterm birth Box-and-whiskers plot of umbilical vein N-terminal pro-brain natriuretic peptide (UV-NT-proBNP) concentration in fetuses with congenital heart defect (CHD) and/or arrhythmia, according to cardiovascular profile (CVP) score, and in controls. All controls had CVP score of 10. Fetuses with CVP score of 6 or 7 and those with CVP score of ≤ 5 had higher UV-NT-proBNP level than did controls (*P < 0.01). No difference was observed in UV-NT-proBNP level between fetuses with CHD and/or arrhythmia and CVP score of ≥ 8 and controls (P = 0.16). Concentration of UV-NT-proBNP in fetuses with CHD and/or arrhythmia was inversely correlated with CVP score (P for trend < 0.01). Boxes indicate median and interquartile range (IQR), whiskers are range excluding outliers more than 1.5 × IQR from upper or lower quartile and circles are outliers. in the CHD and/or arrhythmia group were progression of fetal heart failure or hydropic status (n = 7), spontaneous labor (n = 3) and abnormal fetal heart rate pattern (n = 2). Of the 12 cases of preterm birth, 10 underwent elective Cesarean delivery. One fetus with Ebstein's anomaly with circular shunt (CVP score of 0) born at 34 weeks' gestation had a UA pH of 7.11, and the other case had fetal premature ventricular contraction (CVP score of 8) with a UA pH of 7.14.
Comparison of NP levels in CHD and arrhythmia
Tachy-or bradyarrhythmia but not extrasystole was observed in all 10 fetuses with arrhythmia and CVP score of ≤ 7 at birth. These fetuses had 2.9-fold higher UV-NT-proBNP levels than those with CHD and CVP score of ≤ 7 (10 900 ± 7492 pg/mL vs 3757 ± 5336 pg/mL; P < 0.01) (Figure 3 ). In contrast, in fetuses with a CVP score of ≥ 8, no difference was observed in UV-NT-proBNP level between those with arrhythmia and those with CHD (756 ± 465 pg/mL vs 945 ± 1477 pg/mL; P = 0.49). Among fetuses with a CVP score of ≤ 7, those with CHD and those with arrhythmia had similar last CVP scores (5.7 ± 2.1 vs 5.4 ± 1.4; P = 0.74). However, when comparing each parameter of the last CVP score individually, an abnormal venous Doppler sonography finding was significantly more common and more severe in fetuses with arrhythmia than in those with CHD (P = 0.01) ( Table 4) . Table 4 Comparison of five echocardiographic parameters comprising last cardiovascular profile (CVP) score in 22 fetuses with suspected moderate or severe heart failure (CVP score ≤ 7), in those with congenital heart defect (CHD) vs those with arrhythmia Data are given as mean ± SD or n (%). CVP score is calculated by subtracting points (pt) from initial maximum score of 10. *Tachy-or bradyarrhythmia but not extrasystole was observed in all 10 fetuses with arrhythmia and CVP score ≤ 7 at birth. †Only worst finding was counted for each echocardiographic parameter in last CVP score. All fetuses with pulsatile flow in umbilical vein had reversed ductus venosus flow. All fetuses with skin edema had abdominal, pleural or pericardial effusion. ‡Abnormal venous Doppler sonography findings were significantly more common and more severe in fetuses with tachy-or bradyarrhythmia than in those with CHD (P = 0.01). CAVVR, common atrioventricular valve regurgitation; CTAR, cardiothoracic area ratio; FS, fractional shortening; MR, mitral valve regurgitation; TR, tricuspid valve regurgitation.
NP levels and change in CVP score in utero
Sixteen fetuses with CHD and/or arrhythmia had a decrease in CVP score from enrollment to birth (Table S1) . Fetuses with a decrease in CVP score in utero had a significantly higher neonatal or infant mortality rate compared with those without (17.6% vs 0.9%; P < 0.01).
In the CHD and/or arrhythmia group, fetuses with a decrease in CVP score had moderate or severe atrioventricular valve regurgitation (8/16 (50.0%)), or tachy-or bradyarrhythmia at birth (6/16 (37.5%)); they had a 6-fold higher UV-NT-proBNP level than those without (7099 ± 7859 pg/mL vs 1163 ± 2196 pg/mL; P < 0.01).
Fetuses with a right-heart defect had a lower CVP score than did fetuses with other types of CHD (P = 0.01). Notably, among fetuses with a right-heart defect, those with moderate or severe tricuspid valve regurgitation (TR) had an 11.7-fold higher UV-NT-proBNP level than those without (6755 ± 6264 pg/mL vs 579 ± 771 pg/mL; P < 0.01). However, in fetuses with CHD but without moderate or severe atrioventricular valve regurgitation, UV-NT-proBNP level was not significantly different according to CHD category (P = 0.43). Of the six fetuses with hypoplastic left heart syndrome (HLHS), three had a highly restrictive foramen ovale with an abnormal pulmonary venous flow pattern. All fetuses with HLHS had no change in CVP score in utero and had a low UV-NT-proBNP level (median 920 pg/mL (range, 331-1172 pg/mL)); the results were similar for plasma ANP and BNP levels.
DISCUSSION
This study demonstrates that plasma NP levels in umbilical cord blood are correlated with the severity of heart failure in fetuses with CHD and/or arrhythmia. Fetuses with tachy-or bradyarrhythmia and a right-heart defect with moderate or severe TR showed low CVP scores and high NP levels. Plasma concentrations of UV-ANP, UV-BNP and UV-NT-proBNP were associated with similar heart-failure profiles in fetuses with CHD and/or arrhythmia. Fetal tachy-or bradyarrhythmia at birth was strongly correlated with high NP levels. One major characteristic of the fetal circulation is limited heart-rate reserve. In our study, among fetuses with a CVP score of ≤ 7, abnormal venous Doppler sonography findings were significantly more common and more severe in fetuses with tachy-or bradyarrhythmia than in those with CHD. Moreover, fetuses with tachy-or bradyarrhythmia had higher NP levels than did fetuses with CHD. Abnormal venous Doppler sonography findings indicate elevation in central venous pressure 19 . The increase in wall stress will result in cardiac remodeling and hypertrophy, which increases myocardial oxygen consumption and aggravates myocardial dysfunction. To overcome the reduction in ventricular compliance, end-diastolic filling pressure and hydrostatic central venous pressure will increase to maintain cardiac output, resulting in more release of NP from the fetal heart [19] [20] [21] . Thus, we speculate that high NP levels may be associated with rapid progression to hydrops in fetuses with tachy-or bradyarrhythmia [15] [16] [17] . Right-heart defects with moderate or severe TR were associated with a lower CVP score and higher NP levels than were other types of CHD. Merz et al. 13 reported that fetuses with ventricular outflow tract obstruction and an intact interventricular septum have a significantly higher NT-proBNP level than do fetuses with shunt lesions. They speculated that high ventricular pressure was associated with elevated NP levels. In fact, fetuses with right-heart defect but no or mild TR, which does not lead to high right ventricular pressure, had low NP levels in our study. However, all fetuses with HLHS with a restrictive foramen ovale had low NP levels, even though these were presumed to have high left atrial and ventricular pressures. Taken together, we can safely assume that elevated NP levels can be attributed mainly to increases in central venous pressure secondary to atrioventricular valve regurgitation due to CHD, rather than to the morphological abnormality itself.
Previous studies have reported a correlation between plasma BNP level and the increased preload that is associated with twin-twin transfusion syndrome in monochorionic twin pregnancies 22, 23 . In the case of monochorionic twin pregnancies, however, the release of BNP is altered by several factors such as fetal hypoxemia and renin transfer via placental shunt from the donor twin to the cotwin. In this study, we investigated the relationship between plasma NP levels and fetal heart failure in singletons, in order to exclude twin-related factors.
Compared with controls, no differences were found in NP levels in fetuses with CHD and/or arrhythmia and a CVP score of ≥ 8. This finding reflects the fact that fetuses with a high CVP score do not have heart failure in utero, even though they might have a complex CHD or arrhythmia. Given the physiological advantage of parallel circulation and bypassing of the pulmonary circulation, even fetuses with congenital single ventricle physiology could adapt their circulation in utero 24, 25 . Therefore, mortality after birth cannot be predicted by CVP score and NP levels for some types of CHD. For example, HLHS with a highly restrictive foramen ovale is well known to have a poor prognosis soon after birth 7 , but it was associated with high CVP score and low NP levels in our study.
Preterm birth was correlated independently with high NP levels in our study. Earlier studies have shown that gestational age is not an important determinant of fetal and newborn ANP levels 26, 27 . A study by Ville et al. 27 showed that plasma ANP level was higher in fetuses with hydrops than in controls. Based on these reports, preterm birth caused by fetal heart failure or hydropic status may contribute to high NP levels. Kingdom et al. 26 showed that umbilical-cord ANP level was inversely related to UA pH. Maternal hypertensive disorder and fetal acidemia during labor have been reported to stimulate fetal ANP production 28 . We found that a UA pH of < 7.15 is correlated independently with high NP levels, which is consistent with the findings of these previous studies.
There are several limitations to the present study, including its single-center nature and relatively small sample size. First, the most severe cases resulting in fetal demise were not included in the analysis, because umbilical-cord blood samples were available only for live births. However, our institution is one of the largest tertiary pediatric cardiac centers in Japan, and a variety of complex CHDs and arrhythmias was included in the study cohort. In addition, all fetuses with CHD and/or arrhythmia were diagnosed prenatally with high accuracy and had their CVP score assessed within 1 week before birth. Second, the influence of maternal NPs on fetal NP levels was not completely eliminated. Thus, women with the potential for elevated NP levels, such as those with pre-eclampsia, were excluded from this study 29 . Moreover, the transplacental passage of maternal NP levels has been reported to be negligible 30 . Third, we were not able to investigate the relationship between NP levels and mortality after birth. Because of improvements in transplacental therapy for arrhythmias and neonatal management of severe complex CHDs, there were only four neonatal or infant deaths (3.1%) in the study cohort, so multivariate analysis of mortality was not possible. Larger multicenter prospective studies involving CVP score and NP levels are required to better appreciate factors associated with mortality in fetuses with various types of CHD and arrhythmia. Percutaneous umbilical-cord blood sampling will be necessary to obtain real-time NP values that exclude the stress of labor, although, since this is an invasive procedure, we are planning to develop less invasive methods, such as maternal blood biomarkers reflecting fetal heart failure.
In conclusion, plasma NP levels in fetuses with CHD and/or arrhythmia are correlated with the severity of fetal heart failure. Fetuses with tachy-or bradyarrhythmia or right-heart defect with significant TR show high NP levels. Elevated NP levels are attributed mainly to increases in central venous pressure secondary to arrhythmia or atrioventricular valve regurgitation due to CHD, rather than to the morphological abnormality itself.
